KIF6

KIF6

A gene on chromosome 6p21.2 that encodes a member of the kinesin-like protein family.
References in periodicals archive ?
Matthew Taylor discussed the "step backward" that occurred in genetic risk prediction of coronary artery disease (CAD) with the discovery that variations in the KIF6 gene might not be clinically associated with CAD after all.
Biomarkers discussed in the report include: Cytochrome P450 and Drug Metabolism, Estrogen Receptor and Progesterone, Receptor Status for Breast Cancer, HER2 Overexpression and Herceptin and Tykerb, Epidermal Growth Factor Receptor (EGFR), KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer, BRAF Mutations and Cancer Therapy, UGT1A1 Genetic Variants, 5-Flurouracil Therapy, PIK3CA Genetic Variation, KIF6 Genetic Variation, ALK Genetic Variation.
With the availability of RealTime CMV, the Abbott m2000 system offers a broad menu of assays outside the United States, including tests for HIV-1 viral load, HIV-1 Qualitative, hepatitis B and C viral loads, hepatitis C genotyping, human papillomavirus, Epstein-Barr virus, chlamydia, chlamydia/gonorrhea, colorectal cancer detection, and KIF6, a test to identify patients at risk for coronary heart disease.
As the evidence accumulated for KIF6's role, companies began to look at the development of clinical assays that culminated in a KIF6 genetic-testing assay that was marketed to cardiologists and internists.
Celera Corporation (NASDAQ:CRA) today provided an update on recent scientific findings pertaining to the KIF6 gene variant and its pre-market approval application (PMA) with the United States Food and Drug Administration (FDA) for its KIF6 Genotyping Assay.
The Abbott m2000 system offers a broad menu of assays outside the United States, including tests for HIV-1 viral load, hepatitis B and C viral loads, hepatitis C genotyping, human papillomavirus, cytomegalovirus, Epstein-Barr virus, chlamydia, gonorrhea, colorectal cancer detection, and KIF6, a test to identify patients at risk for coronary heart disease.
Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.
WIESBADEN, Germany, February 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the availability of the CE-marked KIF6 diagnostic test for use on the m2000 instrument system.
In September, Celera signed an agreement with Abbott for distribution of a CE-marked KIF6 test to identify patients at risk of coronary heart disease that is reduced with statin therapy.
The results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) study was presented today by investigators fromthe Medco Research Institute[TM], a subsidiary of Medco Health Solutions, Inc.
Findings Also Show No Significant Difference from Earlier Published Reports by Celera and Others on Case-Control Studies of KIF6